DOCSLIB.ORG

Medical Management of Advanced Heart Failure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Management of Advanced Heart Failure CLINICAL CARDIOLOGY CLINICIAN’S CORNER Medical Management of Advanced Heart Failure Anju Nohria, MD Context Advanced heart failure, defined as persistence of limiting symptoms de- Eldrin Lewis, MD spite therapy with agents of proven efficacy, accounts for the majority of morbidity and mortality in heart failure. Lynne Warner Stevenson, MD Objective To review current medical therapy for advanced heart failure. EART FAILURE HAS EMERGED AS Data Sources We searched MEDLINE for all articles containing the term advanced a major health challenge, in- heart failure that were published between 1980 and 2001; EMBASE was searched from creasing in prevalence as age- 1987-1999, Best Evidence from 1991-1998, and Evidence-Based Medicine from 1995- adjusted rates of myocardial 1999. The Cochrane Library also was searched for critical reviews and meta-analyses Hinfarction and stroke decline.1 Affect- of congestive heart failure. ing 4 to 5 million people in the United Study Selection Randomized controlled trials of therapy for 150 patients or more States with more than 2 million hospi- were included if advanced heart failure was represented. Other common clinical situ- talizations each year, heart failure alone ations were addressed from smaller trials as available, trials of milder heart failure, con- accounts for 2% to 3% of the national sensus guidelines, and both published and personal clinical experience. health care budget. Developments her- Data Extraction Data quality was determined by publication in peer-reviewed lit- alded in the news media increase pub- erature or inclusion in professional society guidelines. lic expectations but focus on decreas- Data Synthesis A primary focus for care of advanced heart failure is ongoing iden- ing disease progression in mild to tification and treatment of the elevated filling pressures that cause disabling symp- moderate stages2,3 or supporting the cir- toms. While angiotensin-converting enzyme inhibitors and ␤-adrenergic agents can culation mechanically for limited peri- slow disease progression and prolong survival, titration and tolerability often present ods in end-stage disease.4 Most of the challenges. Most patients are not eligible for surgical intervention but do benefit from burden of this disease is borne between a medical regimen tailored to individual clinical and hemodynamic profiles and from heart failure management programs that reduce rehospitalization. Survival ranges from these 2 boundaries by patients with ad- 80% at 2 years for patients rendered free of congestion to less than 50% at 6 months vanced heart failure, a quarter of the di- for patients with refractory symptoms, in whom end-of-life options may include hos- agnosed heart failure population. pice care and inactivation of implantable defibrillators. Advanced heart failure is defined as Conclusions Current management of advanced heart failure is based more on con- symptoms limiting daily life (New York sensus than on randomized trials. Systematic investigation should address not only new Heart Association class III or IV) de- therapies but also strategies for selecting and optimizing therapies already available. spite previous therapy with angiotensin- JAMA. 2002;287:628-640 www.jama.com converting enzyme (ACE) inhibitors, diuretics, digoxin, and more recently ␤-adrenergic blocking agents when tol- dex term advanced heart failure. Litera- reviewed from multiple sources.6-10 For erated.5 As the syndrome of heart fail- ture searches prepared during the pro- study selection, randomized controlled ure with preserved left ventricular ejec- cess of establishing 2001 guidelines6 were trials of therapy for at least 150 patients tion fraction (LVEF) is still undergoing also reviewed: EMBASE from 1987- were included if advanced heart failure definition, advanced heart failure with 1999 for English articles on human heart was represented. Other common clini- LVEF of 25% or less is the focus of this failure with emphasis on controlled tri- cal situations were addressed from review (TABLE 1). als and meta-analyses; the Best Evi- dence database from the American Col- Author Affiliation: Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass. Literature Review lege of Physicians from 1991-1998 and Financial Disclosure: Dr Stevenson is a consultant for We conducted a MEDLINE search for all Evidence-Based Medicine from 1995- Scios Inc and Medtronic Inc. Corresponding Author and Reprints: Lynne Warner articles from 1980-2001 using the in- 1999; and the Cochrane Library for meta- Stevenson, MD, Cardiovascular Division, Brigham and analyses of strategies for heart failure,con- Women’s Hospital, 75 Francis St, Tower 3-A, Bos- gestive. Approaches to management ton, MA 02115 (e-mail: [email protected]). See also Patient Page. Clinical Cardiology Section Editor: Michael S. Lauer, specific for advanced heart failure were MD, Contributing Editor. 628 JAMA, February 6, 2002—Vol 287, No. 5 (Reprinted) ©2002 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 MEDICAL MANAGEMENT OF ADVANCED HEART FAILURE Table 1. Characteristics of a Sample of Patients With Advanced Heart Failure Undergoing Evaluation for Heart Transplantation* Characteristics 1000 Patients With Advanced Heart Failure Age, y 51 (12) Men, % 78 Coronary artery disease, % 47 Left ventricular ejection fraction, % 22 (8) Left ventricular diastolic diameter, mm 73 (11) Peak Vo2, mL/kg per min 13 (4) 754 Patients With Repeated Measures Baseline Hemodynamics Hemodynamics After Redesign of Therapy† Right atrial pressure, mm Hg 12 (7) 7 (4) Pulmonary capillary wedge pressure, mm Hg 25 (9) 16 (6) Cardiac index,L·minϪ1 ·mϪ2 2.1 (0.7) 2.6 (0.6) Systemic vascular resistance, dynes/s per cmϪ5 1650 (600) 1150 (300) *Data from Drazner et al.25 Data are presented as mean (SD) unless otherwise indicated. †Hemodynamic improvement obtained primarily on intravenous vasodilators and diuretics with the final measurements made on a revised oral regimen, which included captopril and nitrates in most patients with the occasional substitution or addition of hydralazine. smaller trials, trials of milder heart fail- tients receiving amiodarone. Common Elucidation of Symptoms. Effective ure, consensus guidelines, and clinical viral infections often aggravate heart fail- therapy requires that clinicians thor- experience both published and per- ure for several weeks even after resolu- oughly understand what patients per- sonal. Data quality for extraction was tion of viral symptoms. ceive to be the most limiting aspects of determined by publication in peer- Coronary artery disease is present in their lives. Regular review of specific ac- reviewed literature or inclusion in pro- 50% to 70% of patients with advanced tivities including dressing, climbing fessional society guidelines. heart failure.11 In such patients, the quest stairs, getting the mail, and pushing a for reversible ischemia creates many grocery cart provide better information Evaluation of Advanced questions. Revascularization is sup- than the New York Heart Association Heart Failure ported by controlled data for LVEF rang- class definitions.22 Symptoms of ad- Search for Potentially Reversible Fac- ing from 35% to 50% and by registry data vanced heart failure are dominated by tors. Evaluation of primary cause has for LVEF that is less than 35% with domi- those related to congestion, a reflection been detailed elsewhere.6 Potentially re- nant ischemic symptoms.16 Although of elevated filling pressures.9 High left- versible factors should be sought repeat- noninvasive testing is frequently per- sided filling pressures cause shortness of edly. Atrial fibrillation is present in 25% formed to demonstrate ischemic re- breath or coughing when lying down (or- to 50% of patients with advanced heart gions for revascularization,17,18 there is thopnea) or immediate dyspnea on light failure.11 Left ventricular ejection frac- no controlled evidence for screening or exertion, such as dressing or walking tion and clinical status frequently im- intervention without angina. across a room. Dyspnea occurring after prove after therapy, with continuing con- Left ventriculectomy for nonisch- sustained exercise reflects multiple he- troversy regarding the benefits of emic cardiomyopathy (popularized by modynamic, pulmonary, and skeletal restoring sinus rhythm vs diligent rate Batista) is no longer actively per- muscle abnormalities. Elevated right- control.12-14 Although digoxin may con- formed because poor outcomes were sided filling pressures can cause uncom- trol resting rate, control of ambulatory found.19 For large dyskinetic regions af- fortable edema or ascites, anorexia, early rate generally requires ␤-adrenergic ter infarction, aneurysmectomy may be satiety, abdominal fullness, and discom- blocking agents or amiodarone . undertaken. A proposed modification fort when bending. Symptoms attribut- Heavy alcohol consumption can cause with endocardial patch placement, de- able to low resting cardiac output are less and aggravate heart failure although scribed by Beyersdorf et al,20 is under specific and usually include lack of en- modest use has been associated epide- clinical investigation. Mitral valve re- ergy and fatigue. Daytime sleepiness or miologically with a lower incidence.15 pair or replacement is sometimes con- difficulty concentrating may reflect dis- Obesity not only exacerbates but also can sidered for severe valvular regurgita- turbed nocturnal sleep, severely re- cause cardiomyopathy
Load more

Recommended publications
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Radionuclear Measurement of Peripheral Hemodynamics In
    RadionuclearMeasurementof Peripheral Hemodynamics in Selection of Vasodilators for Treatment of Heart Failure Yasuhiro Todo, Mitsumasa Ohyanagi, Ryu Fujisue, and Tadaaki Iwasaki Hyogo College ofMedicine, Nishinomiya, Japan Inorder to select the optimal vasodilator for the treatment of patients with congestive heart failure (CHF), the acute effects of three vasodilators (isosorbide dinitrate (ISDN) 5 mg, nifedipine 10 mg, and prazosin 1 mg) on peripheral capacitance and resistance vessels (CV and RV)were evaluated by a newly devised radionuclear technique (Study 1).Thirty-six @ patients with chronic CHF were dividedinto Group A (ejectionfraction (EF) 35%, n = 20, mean EF: 47.2 ±6.5%) and B (EF < 35%, n = 16, mean EF: 24.8 ±7.1%). ISDNproduced the strongest CVdilatation(25% in both groups). Nifedipinereduced RVtone in Groups A and B (14% and 27%, respectively),and CVtone in Group A (6%). Prazosin had the most prominent effects on both vessels in Group B. From these results, it appeared: (a) ISDN is indicated for the cases with increased CV tone, (b) nifedipine is suitable for those with @ increased RV tone, (C)in cases of increased tone in both vessels, nifedipine (when EF 35%) or prazosin (when EF < 35%) is optimal.To evaluate the validityof this assignment, 49 subjects with CHF were divided into Group 1 (n = 16, increased CV tone), Group 2 (n = 17, increased RV tone), and Group 3 (n = 16, increased CV and RV tone) in Study 2. In Group 1, the changes of all indexes were not significantly different between the subjects treated with optimal drug based on the assignment (subgroup P) and those with a non-optimaldrug (subgroup N)after 2 wk of therapy.
    [Show full text]
  • A Textbook of Clinical Pharmacology and Therapeutics This Page Intentionally Left Blank a Textbook of Clinical Pharmacology and Therapeutics
    A Textbook of Clinical Pharmacology and Therapeutics This page intentionally left blank A Textbook of Clinical Pharmacology and Therapeutics FIFTH EDITION JAMES M RITTER MA DPHIL FRCP FMedSci FBPHARMACOLS Professor of Clinical Pharmacology at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK LIONEL D LEWIS MA MB BCH MD FRCP Professor of Medicine, Pharmacology and Toxicology at Dartmouth Medical School and the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA TIMOTHY GK MANT BSC FFPM FRCP Senior Medical Advisor, Quintiles, Guy's Drug Research Unit, and Visiting Professor at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK ALBERT FERRO PHD FRCP FBPHARMACOLS Reader in Clinical Pharmacology and Honorary Consultant Physician at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK PART OF HACHETTE LIVRE UK First published in Great Britain in 1981 Second edition 1986 Third edition 1995 Fourth edition 1999 This fifth edition published in Great Britain in 2008 by Hodder Arnold, an imprint of Hodden Education, part of Hachette Livre UK, 338 Euston Road, London NW1 3BH http://www.hoddereducation.com ©2008 James M Ritter, Lionel D Lewis, Timothy GK Mant and Albert Ferro All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency.
    [Show full text]
  • Relationship Between Vasodilatation and Cerebral Blood Flow Increase in Impaired Hemodynamics: a PET Study with the Acetazolamide Test in Cerebrovascular Disease
    CLINICAL INVESTIGATIONS Relationship Between Vasodilatation and Cerebral Blood Flow Increase in Impaired Hemodynamics: A PET Study with the Acetazolamide Test in Cerebrovascular Disease Hidehiko Okazawa, MD, PhD1,2; Hiroshi Yamauchi, MD, PhD1; Hiroshi Toyoda, MD, PhD1,2; Kanji Sugimoto, MS1; Yasuhisa Fujibayashi, PhD2; and Yoshiharu Yonekura, MD, PhD2 1PET Unit, Research Institute, Shiga Medical Center, Moriyama, Japan; and 2Biomedical Imaging Research Center, Fukui Medical University, Fukui, Japan Key Words: acetazolamide; cerebrovascular disease; cerebral The changes in cerebral blood flow (CBF) and arterial-to- blood volume; vasodilatory capacity; cerebral perfusion pressure capillary blood volume (V0) induced by acetazolamide (ACZ) are expected to be parallel each other in the normal circula- J Nucl Med 2003; 44:1875–1883 tion; however, it has not been proven that the same changes in those parameters are observed in patients with cerebro- vascular disease. To investigate the relationship between changes in CBF, vasodilatory capacity, and other hemody- namic parameters, the ACZ test was performed after an The ability of autoregulation to maintain the cerebral 15O-gas PET study. Methods: Twenty-two patients with uni- blood flow (CBF), which resides in the cerebral circulation lateral major cerebral arterial occlusive disease underwent despite transient changes in systemic mean arterial blood 15 PET scans using the H2 O bolus method with the ACZ test pressure, has been shown to occur via the mechanism of 15 after the O-gas steady-state method. CBF and V0 for each arteriolar vasodilatation in the cerebral circulation (1). The subject were calculated using the 3-weighted integral vasodilatory change in the cerebral arteries is assumed for method as well as the nonlinear least-squares fitting method.
    [Show full text]
  • Hemodynamic Effects of Vasodilators and Long-Term Response in Heart Failure
    JACC Vol. 3, No.6 1521 June 1984:1521-30 REPORTS ON THERAPY Hemodynamic Effects of Vasodilators and Long-Term Response in Heart Failure JOSEPH A. FRANCIOSA, MD, FACC, W. BRUCE DUNKMAN, MD, FACC,* CHERYL L. LEDDY, MD* Philadelphia, Pennsylvania and Little Rock, Arkansas Hemodynamic responses to vasodilators are commonly ml/min per kg (p < 0.01), and exercise duration also assessed when starting long-term vasodilator treatment increased by 1.8 ± 3.5 minutes (p < 0.01). Changes in in patients with chronic left ventricular failure, although maximal oxygen uptake, however, did not correlate with the relation between short- and long-term responses is short-term changes in pulmonary wedge pressure (cor• not established. Thus, short- and long-term hemody• relation coefficient [r] = - 0.14), cardiac index (r = namic responses to placebo and vasodilators (isosorbide - 0.01) or systemic vascular resistance (r = - 0.20). dinitrate, minoxidil and enalapril or captopril) were Long-term hemodynamic changes also failed to correlate measured and long-term clinical efficacy was assessed with changes in exercise capacity. Baseline hemody• by changes in exercise capacity after 1 to 5 months of namics, cardiac dimensions and left ventricular ejection vasodilator administration (plus digitalis and diuretic fraction before vasodilator administration all failed to agents) in 46 patients with New York Heart Association correlate with baseline exercise capacity or with long• fun~tional class II to IV heart failure caused by cardio• term changes in exercise capacity. myopathy. There were no significant changes in hemo• Thus, hemodynamic measurements at initiation or dynamics or exercise capacity during placebo treatment.
    [Show full text]
  • The Evolution of Heart Failure with Reduced Ejection Fraction Pharmacotherapy: What Do We Have and Where Are We Going?
    Pharmacology & Therapeutics 178 (2017) 67–82 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: M. Curtis The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? Ahmed Selim, Ronald Zolty, Yiannis S. Chatzizisis ⁎ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA article info abstract Available online 21 March 2017 Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many Keywords: other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery Heart failure of treatments to improve the survival and quality of life of patients with heart failure; many were successful, Reduced ejection fraction while others failed. Given that most of the successes in treating heart failure were achieved in patients with re- Pharmacotherapy duced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of Novel drugs HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate poten- tial treatment targets and pathways that might play a role in treating HFrEF in the future. © 2017 Elsevier Inc. All rights reserved. Contents 1. Introduction..............................................
    [Show full text]
  • Investigations Into the Role of Nitric Oxide in Disease
    INVESTIGATIONS INTO THE ROLE OF NITRIC OXIDE IN CARDIOVASCULAR DEVXLOPMENT DISEASE: INSIGHTS GAINED FROM GENETICALLY ENGINEERED MOUSE MODELS OF HUMAN DISEASE Tony Lee A thesis submitted in conformity with the requirements for the degree of Master's of Science Institute of Medicai Science University of Toronto @ Copyright by Tony C. Lee (2000) National Library Bibliothèque nationale I*I of Canada du Canada Acquisitions and Acquisitions et Bibliogaphic Services services bibliogaphiques 395 Wellington Street 395, rue Wellington Ottawa ON K1A ON4 Ottawa ON KIA ON4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distribuer ou copies of this thesis in microfonn, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/nlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fkom it Ni la thèse ni des extraits substantiels may be printed or othewise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. INVESTIGATIONS INTO THE ROLE OF MTNC OXIDE IN CARDIOVASCULAR DEVELOPMENT AND DISEASE: INSIGHTS GAiNED FROM GENETICALLY ENGINEERED MOUSE MODELS OF HUMAN DISEASE B y Tony Lee A thesis submitted in conformity with the requirements for the degree of Master's of Science (2000) Instinite of Medical Science, University of Toronto In the first expenmental series, the antiatherosclerotic effects of Enalûpril vrrsus Irbesartan were compared in the LDL-R knockout mouse model.
    [Show full text]
  • Hair Growth Stimulation with Nitroxide and Other Radicals
    Europaisches Patentamt 263 European Patent Office © Publication number: 0 327 Office europeen des brevets A1 © EUROPEAN PATENT APPLICATION © Application number: 89300785.6 © Int. CI.4: A61 K 7/06 , A61K 47/00 © Date of filing: 27.01.89 © Priority: 29.01.88 US 149720 © Applicant: PROCTOR, Peter H. Twelve Oaks Medical Tower 4125 Southwest © Date of publication of application: Freeway 09.08.89 Bulletin 89/32 Suite 1616 Houston, TX 77027(US) © Designated Contracting States: © Inventor: PROCTOR, Peter H. AT BE CH OE ES FR GB GR IT Li LU NL SE Twelve Oaks Medical Tower 4125 Southwest Freeway Suite 1616 Houston, TX 77027(US) © Representative: Gore, Peter Manson et al W.P. THOMPSON & CO. Coopers Building Church Street Liverpool L1 3AB(GB) © Hair growth stimulation with nitroxide and other radicals. © Hair growth stimulation with nitroxide and other radicals. A nitroxide radical source compound is applied topically with an adjuvant selected from reducing agents, hydroxyl radical scavengers and antioxidants to activate formation of the nitroxide radical and/or to protect the nitroxide radical from reaction with other free radicals. Also disclosed is a kit for preparing a unit dose for topical application of a nitric oxide generating compound and a reducing agent reactive therewith to form nitric oxide on or in the skin. Other adjuvants include SOD and antiandrogens. Various other radical-forming hair growth stimulants and preparations thereof are disclosed. < w CO CM IN CM CO © Q. Ill Xerox Copy Centre EP 0 327 263 A1 rIAIR GROWTH STIMULATION WITH NITROXIDE AND OTHER RADICALS This invention relates to a composition and method for stimulating hair growth, and to a kit for preparation of such a composition.
    [Show full text]
  • 682.Full.Pdf
    Endogenous and nitrovasodilator-induced release of NO in the airways of end-stage cystic fibrosis patients To the Editors: blood pressure changes recorded, as described previously [8] and in the online supplementary material. A variety of isoforms of nitric oxide (NO) synthases are constitutively expressed in human airway and vascular Nearly undetectable levels of NO were found in CF patients endothelial cells continuously generating NO. NO plays an representing an output of 7.6¡6 ppb over 30 s. This is in important role in regulating lung function in health and contrast to patients presented for routine open heart surgery disease including modulation of pulmonary vascular resis- (91.4¡21 ppb over 30 s; fig. 1). Representative traces are tance, airway calibre and host defence. Production of NO and shown in figure 1A and C of the online supplementary its consumption by fluid-phase reactions can be detected and material. monitored in the exhaled air, providing an important window There was a significant increase in gas-phase NO above baseline to assess the dynamics of NO metabolism in health and levels by 250 mg GTN boluses in CF patients (36.7¡6ppb), inflammatory lung conditions, asthma in particular [1]. which was comparable to that seen in control patients with A series of milestone studies uncovered a relative deficiency of routine open heart surgery (48.7¡4 ppb; fig. 1). Representative pulmonary NO availability in cystic fibrosis (CF), a severe traces of GTN-induced exhaled NO are presented in figure 1B chronic inflammatory lung disease with studies generally and D of the online supplementary material.
    [Show full text]
  • Chapter 9 Monitoring of the Heart and Vascular System
    Chapter 9 Monitoring of the Heart and Vascular System David L. Reich, MD • Alexander J. Mittnacht, MD • Martin J. London, MD • Joel A. Kaplan, MD Hemodynamic Monitoring Cardiac Output Monitoring Arterial Pressure Monitoring Indicator Dilution Arterial Cannulation Sites Analysis and Interpretation Indications of Hemodynamic Data Insertion Techniques Systemic and Pulmonary Vascular Resistances Central Venous Pressure Monitoring Frank-Starling Relationships Indications Monitoring Coronary Perfusion Complications Electrocardiography Pulmonary Arterial Pressure Monitoring Lead Systems Placement of the Pulmonary Artery Catheter Detection of Myocardial Ischemia Indications Intraoperative Lead Systems Complications Arrhythmia and Pacemaker Detection Pacing Catheters Mixed Venous Oxygen Saturation Catheters Summary References HEMODYNAMIC MONITORING For patients with severe cardiovascular disease and those undergoing surgery associ- ated with rapid hemodynamic changes, adequate hemodynamic monitoring should be available at all times. With the ability to measure and record almost all vital physi- ologic parameters, the development of acute hemodynamic changes may be observed and corrective action may be taken in an attempt to correct adverse hemodynamics and improve outcome. Although outcome changes are difficult to prove, it is a rea- sonable assumption that appropriate hemodynamic monitoring should reduce the incidence of major cardiovascular complications. This is based on the presumption that the data obtained from these monitors are interpreted correctly and that thera- peutic decisions are implemented in a timely fashion. Many devices are available to monitor the cardiovascular system. These devices range from those that are completely noninvasive, such as the blood pressure (BP) cuff and ECG, to those that are extremely invasive, such as the pulmonary artery (PA) catheter. To make the best use of invasive monitors, the potential benefits to be gained from the information must outweigh the potential complications.
    [Show full text]
  • Hemodynamic Parameters in the Assessment of Fluid Status in A
    PERIOPERATIVE MEDICINE ABSTRACT Background: Measuring fluid status during intraoperative hemorrhage is challenging, but detection and quantification of fluid overload is far more diffi- cult. Using a porcine model of hemorrhage and over-resuscitation, it is hypoth- Hemodynamic Parameters esized that centrally obtained hemodynamic parameters will predict volume status more accurately than peripherally obtained vital signs. in the Assessment Methods: Eight anesthetized female pigs were hemorrhaged at 30 ml/min to a blood loss of 400 ml. After each 100 ml of hemorrhage, vital signs (heart of Fluid Status in a rate, systolic blood pressure, mean arterial pressure, diastolic blood pressure, pulse pressure, pulse pressure variation) and centrally obtained hemodynamic Porcine Hemorrhage and parameters (mean pulmonary artery pressure, pulmonary capillary wedge pressure, central venous pressure, cardiac output) were obtained. Blood Resuscitation Model volume was restored, and the pigs were over-resuscitated with 2,500 ml of crystalloid, collecting parameters after each 500-ml bolus. Hemorrhage Eric S. Wise, M.D., Kyle M. Hocking, Ph.D., and resuscitation phases were analyzed separately to determine differences Monica E. Polcz, M.D., Gregory J. Beilman, M.D., among parameters over the range of volume. Conformity of parameters during Colleen M. Brophy, M.D., Jenna H. Sobey, M.D., hemorrhage or over-resuscitation was assessed. Philip J. Leisy, M.D., Roy K. Kiberenge, M.D., Bret D. Alvis, M.D. Results: During the course of hemorrhage, changes from baseline euvolemia were observed in vital signs (systolic blood pressure, diastolic blood pressure, ANESTHESIOLOGY 2021; 134:607–16 and mean arterial pressure) after 100 ml of blood loss.
    [Show full text]
  • Management of Preoperative Hypertension
    PRINTER-FRIENDLY VERSION AVAILABLE AT ANESTHESIOLOGYNEWS.COM Management of Preoperative Hypertension All rights reserved. Reproduction in whole or in part without permission is prohibited. PETER J. PAPADAKOS, MD, FCCM, FAARC Copyright © 2015 McMahon PublishingDirector Groupof Critical unless Care Medicine otherwise noted. University of Rochester Medical Center School of Medicine and Dentistry Rochester, New York Editorial Advisory Board Member Anesthesiology News KEITH M. FRANKLIN, MD Department of Anesthesiology University of Rochester Medical Center School of Medicine and Dentistry Rochester, New York The authors reported no relevant financial disclosures. ystemic hypertension is an extremely common diagnosis in Sthe US surgical population, with approximately 30% of Americans having the condition. Published studies have shown that the incidence of Management Guidelines hypertension in preoperative patients ranges from 10% The Eighth Joint National Committee (JNC 8) panel to 25%.1 The main risk for preoperative hypertension is released the current Guidelines for Management of High intraoperative hemodynamic instability; both hyper- Blood Pressure in Adults in 2014.3 It is notable that, in tension and hypotension are significantly more com- contrast to JNC 7, these guidelines do not define pre- mon in patients who present as hypertensive.2 Patients hypertension and hypertension, nor do they subdivide who experience instability may go on to develop fur- hypertension into stages based on severity. The new ther sequelae such as stroke and myocardial ischemia. guidelines are more practical in nature and focus on The onset of end-organ damage and the urgency of outlining a set of parameters for initiation and goals of the case are important factors when deciding whether treatment.
    [Show full text]